^
Association details:
| Biomarker: | BRAF G596V |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
Excerpt:
From the 6 patients with non-V600E, one (17%) with G596V had PR with vemurafenib….One patient with G596V achieved PR with vemurafenib.
DOI:
10.1097/JTO.0000000000000625
